EPO and type 2 diabetes mellitus: There is strong evidence demonstrating SGLT2-inhibition inducing erythropoiesis; a 12-week study reported increased haematocrit, haemoglobin, reticulocyte count and erythropoietin (EPO) with dapagliflozin [99], with similar results in a trial using empagliflozin in patients with T2DM and ishcaemic heart disease [100].